Revenue growth remains non-existent with a -100% contraction in 2026Q1, while net margins consistently reflect deep operational inefficiency, often exceeding -500% in recent periods.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 |
|---|
| Sales/Revenue | 3K | 6K | 11K | 9K | 88.6K | 87.75K | 164.5K | 165.5K | 124.4K | 4.8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -78.57% | -45.45% | 22.22% | -89.84% | 0.96% | -46.65% | -0.6% | 33.04% | 2491.67% | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 29.85K | 2.19K | 4.4K | 3.6K | 28.49K | 47.95K | 50.6K | 45.5K | 70.38K | 8K | 766.07K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 36.57% | 40% | 40% | 32.16% | 54.64% | 30.76% | 27.49% | 56.57% | 166.67% | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -26.85K | 3.81K | 6.6K | 5.4K | 60.11K | 39.8K | 113.9K | 120K | 54.02K | -3.2K | -766.07K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | -894.97% | 63.43% | 60% | 60% | 67.84% | 45.36% | 69.24% | 72.51% | 43.43% | -66.67% | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -42.33% | 22.22% | -91.02% | 51.01% | -65.05% | -5.08% | 122.12% | 1788.28% | 99.58% | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 5.91M | 6.15M | 5.75M | 5.63M | 10.3M | 3.17M | 1.23M | 1.25M | 1.17M | 1.17M | 759.67K | 20.83K | 19.43K | 20.12K | 20.1K | 19.83K | 14.29K | 30.55K | 53.49K | 13.62K | 1.43K |
| OpEx % of Revenue | - | 102443.67% | 52276.92% | 62505.91% | 11630.34% | 3607.53% | 746.95% | 755.39% | 939.11% | 24470.96% | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.76M | 3.76M | 3.24M | 3.56M | 3.94M | 2.96M | 1.16M | 1.22M | 1.05M | 898.53K | 664.98K | 20.83K | 19.43K | 20.12K | 20.1K | 19.83K | 14.29K | 30.55K | 53.49K | 13.62K | 1.43K |
| SG&A % of Revenue | - | 62724.95% | 29447.56% | 39558.99% | 4450.95% | 3378.18% | 706.35% | 739.11% | 844.44% | 18719.29% | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 2.06M | 2.26M | 2.4M | 1.97M | 6.27M | 109.18K | 0 | 0 | 96.62K | 260.08K | 85.33K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | 37663.27% | 21825.25% | 21895.99% | 7075.46% | 124.42% | - | - | 77.67% | 5418.44% | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 92.75K | 123.33K | 110.45K | 94.58K | 92.08K | 92.08K | 66.79K | 26.95K | 21.14K | 0 | 9.36K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -5.94M | -6.14M | -5.74M | -5.62M | -10.24M | -3.13M | -1.11M | -1.13M | -1.11M | -1.18M | -766.07K | -20.83K | -19.43K | -20.12K | -20.1K | -19.83K | -14.29K | -30.55K | -53.49K | -13.62K | -1.43K |
| Operating Margin % | -198049.63% | -102380.23% | -52216.92% | -62445.91% | -11562.5% | -3562.17% | -677.71% | -682.88% | -895.68% | -24537.63% | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -6.95% | -2.2% | 45.14% | -227.72% | -180.4% | 1.36% | -1.43% | 5.4% | -53.75% | -3577.56% | -7.23% | 3.45% | -0.12% | -1.34% | -38.77% | 53.23% | 42.88% | -292.82% | -851.57% | - |
| EBITDA | -5.82M | -6.02M | -5.63M | -5.53M | -10.15M | -3.03M | -1.05M | -1.1M | -1.09M | -1.16M | -756.72K | -20.83K | -19.43K | -20.12K | -20.1K | -19.83K | -14.29K | -30.55K | -53.49K | -13.62K | -1.43K |
| EBITDA Margin % | -193996.13% | -100324.78% | -51212.81% | -61394.98% | -11458.56% | -3457.24% | -637.11% | -666.6% | -878.68% | -24204.42% | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 5.67% | -6.85% | -1.95% | 45.57% | -234.63% | -189.48% | 5% | -0.93% | 5.92% | -53.53% | -3532.64% | -7.23% | 3.45% | -0.12% | -1.34% | -38.77% | 53.23% | 42.88% | -292.82% | -851.57% | - |
| D&A (Non-Cash Add-back) | 121.61K | 123.33K | 110.45K | 94.58K | 92.08K | 92.08K | 66.79K | 26.95K | 21.14K | 15.99K | 9.36K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | -5.94M | -6.14M | -5.74M | -5.62M | -10.24M | 23.49M | -35.1M | -6.59M | -12.29M | -1.18M | -759.67K | -20.83K | -19.43K | -20.12K | -20.1K | -19.83K | -14.29K | -30.55K | -51.27K | 0 | 0 |
| Net Interest Income | 180.86K | 147.81K | 250.38K | 333.56K | 100.33K | -4.28M | -1.23M | -1.9M | -1.36M | -377.59K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 180.86K | 147.81K | 250.38K | 333.56K | 100.33K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 469 | 2.33K | 1.95K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 4.28M | 1.23M | 1.9M | 1.36M | 377.59K | 6.4K | 9.93K | 8.59K | 7.16K | 5.49K | 4.22K | 2.97K | 1.06K | 0 | 0 | 0 |
| Other Income/Expense | 180.86K | 147.81K | 250.38K | 333.56K | 100.33K | 22.34M | -35.21M | -7.35M | -12.54M | -1.48M | -6.4K | -9.93K | -8.59K | -7.16K | -5.49K | -4.22K | -2.97K | -1.06K | 2.22K | 2.33K | 1.95K |
| Pretax Income | -5.76M | -6M | -5.49M | -5.29M | -10.14M | 19.21M | -36.33M | -8.48M | -13.66M | -2.66M | -766.07K | -30.76K | -28.01K | -27.28K | -25.59K | -24.05K | -17.26K | -31.61K | -51.27K | -11.29K | 523 |
| Pretax Margin % | -192020.93% | -99916.8% | -49940.74% | -58739.71% | -11449.26% | 21892.75% | -22082.21% | -5126.09% | -10977.21% | -55398.08% | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -661 | 162 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 5.86% | 30.98% |
| Net Income | -5.76M | -6M | -5.49M | -5.29M | -10.14M | 19.21M | -36.33M | -8.48M | -13.66M | -2.66M | -766.07K | -30.76K | -28.01K | -27.28K | -25.59K | -24.05K | -17.26K | -31.61K | -52.64K | -9.54K | 1.37K |
| Net Margin % | -192066.27% | -99916.8% | -49940.74% | -58739.71% | -11449.26% | 21892.75% | -22082.21% | -5126.09% | -10977.21% | -55398.08% | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 5.39% | -9.13% | -3.91% | 47.88% | -152.8% | 152.89% | -328.18% | 37.87% | -413.54% | -247.11% | -2390.4% | -9.81% | -2.68% | -6.63% | -6.36% | -39.4% | 45.41% | 39.95% | -451.51% | -795.63% | - |
| Net Income (Continuing) | -5.76M | -6M | -5.49M | -5.29M | -10.14M | 19.21M | -36.33M | -8.48M | -13.66M | -2.66M | -766.07K | -30.76K | -28.01K | -27.28K | -25.59K | -24.05K | -17.26K | -31.61K | -51.27K | -9.54K | 1.37K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 23.36K | 10K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.56 | -2.52 | -3.71 | -3.76 | -9.28 | 56.10 | -626.88 | -5017.67 | -11351.33 | -17379.79 | -5471.94 | -1281.71 | -1167.17 | -1136.75 | -1066.04 | -1002.29 | -719.00 | -1317.08 | -2193.17 | -397.67 | 57.17 |
| EPS Growth % | 45.67% | 32.08% | 1.33% | 59.48% | -116.54% | 108.95% | 87.51% | 55.8% | 34.69% | -217.62% | -326.93% | -9.81% | -2.68% | -6.63% | -6.36% | -39.4% | 45.41% | 39.95% | -451.5% | -795.59% | - |
| EPS (Basic) | - | -2.52 | -3.71 | -3.76 | -9.28 | 73.75 | -626.88 | -5017.67 | -11351.33 | -17379.79 | -5471.94 | -1281.71 | -1167.17 | -1136.75 | -1066.04 | -1002.29 | -719.00 | -1317.08 | -2193.17 | -397.67 | 57.17 |
| Diluted Shares Outstanding | 3.7M | 2.38M | 1.48M | 1.41M | 1.09M | 324.86K | 57.95K | 2.07K | 1.2K | 153 | 140 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Basic Shares Outstanding | 3.7M | 2.38M | 1.48M | 1.41M | 1.09M | 260.5K | 57.95K | 2.07K | 1.2K | 153 | 140 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Binary clinical trial failure
As reported in recent financial filings, CELZ's revenue trajectory remains negligible, with a -100% growth rate in the most recent quarter and a lack of consistent top-line generation, suggesting the company's current commercial strategy for its urology products is failing to gain any meaningful market traction.
The absence of recurring revenue indicates that the company has yet to transition from a research-oriented entity to a commercial enterprise. Investors should monitor whether the lack of growth is a result of product-market mismatch or an intentional pivot toward long-term clinical development.
Based on the company's income statement, the massive disparity between R&D and SG&A expenditures and the near-zero revenue suggests an unsustainable cost structure that relies entirely on external capital to fund ongoing operations rather than internal cash generation from its core regenerative medicine product line.
The company's cost structure is heavily weighted toward administrative and research overhead, which appears to be disconnected from any measurable commercial success. This suggests that the current burn rate is likely to continue until a significant clinical milestone is achieved or the company faces a liquidity event.
According to historical income statements, the company's net losses are consistently driven by high operating expenses, with net margins frequently exceeding -500%, indicating that the reported earnings quality is poor and primarily reflects the high cost of maintaining a public listing and clinical research pipeline.
The persistent net losses and lack of positive EPS suggest that the company is not currently optimized for profitability. Analysts should be wary of the potential for future equity dilution as the company continues to fund these losses through capital markets.
While the company maintains a $7.2M cash position, the extreme disconnect between this liquidity and the $6,000 in TTM revenue, as noted in recent filings, suggests that the market may be overvaluing the firm's intellectual property relative to its actual ability to execute a commercial rollout.
Short-sellers would likely focus on the high probability of continued cash burn and the lack of evidence that the company's stem cell protocols can be successfully commercialized. The current valuation appears to be a speculative bet on future clinical outcomes rather than a reflection of current operational performance.
Quick answers to the most common questions about buying CELZ stock.
For fiscal year 2025, Creative Medical Technology Holdings, Inc. (CELZ) reported total revenue of $0.0M.
Creative Medical Technology Holdings, Inc. (CELZ) reported a net loss of $6.0M for the fiscal year ending 2025.
Creative Medical Technology Holdings, Inc. (CELZ) reported an operating income of $-6.1M, resulting in an operating profit margin of -102380.2%. This margin reflects the operational efficiency of the business before interest and taxes.
Creative Medical Technology Holdings, Inc. (CELZ) generated $0.0M in gross profit for the year, representing a gross profit margin of 63.4%. This demonstrates the company's core pricing power and production efficiency.